Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
Summary
GlobalData's Medical Devices sector report, “Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Transmucosal Drug Delivery pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Transmucosal Drug Delivery device is intended for the localized delivery of medications through a mucous membrane.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Transmucosal Drug Delivery under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Transmucosal Drug Delivery and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Transmucosal Drug Delivery under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 Transmucosal Drug Delivery Overview
4 Products under Development
4.1 Transmucosal Drug Delivery - Pipeline Products by Stage of Development
4.2 Transmucosal Drug Delivery - Pipeline Products by Segment
4.3 Transmucosal Drug Delivery - Pipeline Products by Territory
4.4 Transmucosal Drug Delivery - Pipeline Products by Regulatory Path
4.5 Transmucosal Drug Delivery - Pipeline Products by Estimated Approval Date
4.6 Transmucosal Drug Delivery - Ongoing Clinical Trials
5 Transmucosal Drug Delivery - Pipeline Products under Development by Companies
5.1 Transmucosal Drug Delivery Companies - Pipeline Products by Stage of Development
5.2 Transmucosal Drug Delivery – Companies Pipeline Products by Stage of Development
6 Transmucosal Drug Delivery Companies and Product Overview
7.1 May 12, 2023: Impel Pharmaceuticals announces first quarter 2023 financial results and provides business update
7.2 May 10, 2023: AcelRx Pharmaceuticals reports first quarter 2023 financial results and provides corporate update
7.3 May 04, 2023: Daré Bioscience to host Q1 2023 financial results and company update conference call and webcast on May 11, 2023
7.4 Apr 28, 2023: Candace Matthews elected independent chairperson of Aptar’s board of directors
7.5 Apr 12, 2023: Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors
7.6 Mar 31, 2023: Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update
7.7 Mar 30, 2023: Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
7.8 Mar 24, 2023: Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
7.9 Mar 17, 2023: Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
7.10 Feb 16, 2023: Marinomed Biotech announces preliminary revenue for 2022 with double-digit growth for Carragelose
7.11 Dec 02, 2022: Neurelis to present nine posters at the 76th American Epilepsy Society Annual Meeting
7.12 Nov 30, 2022: Optinose announces corporate updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
7.13 Nov 30, 2022: Recipharm invests in its single dose nasal platform capabilities
7.14 Nov 22, 2022: Distinguished Cancer and Stem Cell Biologist Ulrich Steidl M.D. Ph.D. Appointed Chair of Cell Biology at Albert Einstein College of Medicine
7.15 Nov 14, 2022: AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7.16 Nov 10, 2022: Dare Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
7.17 Nov 10, 2022: Aptar Mumbai announces new facility construction
7.18 Nov 04, 2022: Avanir files WARN notice for 100+ layoffs from California as merger with parent Otsuka looms
7.19 Nov 01, 2022: Cognitive Research Corp. Appoints Jeff Williams as Executive Chairman Following Growth Equity Transaction
7.20 Nov 01, 2022: New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells
7.21 Oct 31, 2022: Aptar Pharma completes first phase of global injectables expansion program
7.22 Oct 18, 2022: Aptar Digital Health announces strategic partnership with the Chiesi Group
7.23 Oct 11, 2022: Aptar Digital Health launches new disease management platform
7.24 Aug 15, 2022: Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
7.25 Aug 12, 2022: AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7.26 Jul 28, 2022: Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
7.27 Jul 13, 2022: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results
Table 26: Altamira Medica AG - Ongoing Clinical Trials Overview
Table 27: Bentrio - Viral Infections - A Randomized, Placebo-controlled Clinical Study to Evaluate the Ability of Bentrio Nasal Spray in COVID-19 Patients: COVAMID
Table 28: Bentrio - Viral Infections - Study Evaluating the Efficacy of Bentrio Nasal Spray for Protection Against Airborne Viruses and Allergens in India
Table 93: BXCL501 Sublingual Film - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of BXCL501 Over a 12 Week Treatment Period in Subjects with Agitation Associated with Dementia
Table 94: BXCL501 Sublingual Film - A Study to Evaluate the BXCL501 for At-home Use in Patients with Bipolar Disorder or Schizophrenia
Table 130: DARE-HRT1 Intravaginal Ring - A Phase 1/2, Open-label, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of DARE-HRT1 (80ug Estradiol/4 Mg Progesterone and 160ug Estradiol/8 Mg Progesterone Intravaginal Rings) Over 12 Weeks in Healthy Postmenopausal Women
Table 138: SIAN - Phase 1, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Stabilized Isoam